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Evidence Based Medicine (EBM) is an approach to clinical practice that relies on the 
use of systematically reviewed published clinical research of high quality. Whilst there is 
some speculation as to whether a true consensus definition of EBM exists (Loughlin 
(2008)(1)), a commonly cited explanation “the conscientious, explicit, and judicious use of 
current best evidence in making decisions about the care of individual patients’ (Sackett et al 
(1996)(2)). Most approaches to “EBM” incorporate the use of an evidence hierarchy that 
presupposes that some forms of evidence are better than others (Guyatt and Rennie 
(2002)(3)), that meta-analyses and randomised controlled trials (RCTs) will guide a better 
level of care than expert or local knowledge.  
Although EBM is pervasive throughout all health literature a number of ethical 
(Gupta (2009)(4)), epistemological (Loughlin (2008)(1)), and clinical practice critiques (Tobin 
(2008)(5)) have emerged. Criticisms of EBM on ethical grounds have previously been 
summarised by Kerridge (2010)(6) and include ; “that the implicit and explicit requirement 
for RCTs may lead to unnecessary research being done where sufficient evidence already 
exists;... that methods privileged by EBM, most notably the RCT, are methodologically 
unable to answer questions related to individual patients;.... that evidence hierarchies are 
inadequate and misleading;.... that the dataset that EBM draws from is systematically 
bias[ed],.... that the translation of evidence into practice through clinical practice guidelines 
and decision aids is both ethically and epistemologically problematic...[and] that evidence is 
not value-neutral and cannot be easily translated into practice.” 
The cultural biases implicit within EBM had been noted by Rogers (2004)(7) who 
when examining the impact of EBM on the socially disadvantaged demonstrated the cultural 
bias within EBM. The socially disadvantaged are excluded from the production of evidence 
and consequently “remain disenfranchised from the goods of EBM”. Such is the power 
bestowed upon published research findings that once demonstrated, the imperative to 
implement management “proven” to be effective is greater than any regard of a 
community’s health priorities or with consideration of “robust justice related reasons” for 
implementing such an approach.  The research is able to answer whether a treatment is 
effective but EBM fails to help the medical and wider community determine whether such 
treatment should be pursued.  
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Such biases within EBM extend beyond that of the socially disadvantaged and the 
exclusion (or comparative reduction of) other population groups are commented on widely 
in the literature. The subjects of large RCTs are more likely to be male, less than 65 years old, 
white and educated. Essentially all main stream A* graded journals invite only manuscripts 
written in English, and despite a massive increase in biomedical research being undertaken 
in the 5 BRICS  countries (Brazil, Russia, India, China and South Africa), emphasis in clinical 
practice remains on evidence produced in Northern Europe and North America. Similar 
commentary with regards to the lower engagement of women with the production of 
clinical epidemiology is made by Goldenberg (2010)(8).  As EBM insists upon the 
incorporation of such published evidence it implicitly sanctions such biases and 
consequently is therefore becomes a biased approached to clinical decision making.  
The cultural biases with EBM can be considered within a framework including the 
research agenda, formation of research questions, conduct of trials, translation into practice 
and access to results. 
The research agenda, those areas of health which are considered a priority by those 
funding research projects is the first cultural bias of EBM. Such the majority of funding for 
therapeutic trials comes from pharmaceutical companies(9) there exists (sometimes 
implicitly) a pressure to produce trials that will ultimately be of financial benefit to the 
company. Such an agenda does not necessarily represent the true health needs of a 
community (either in the medically developed or non-developed world). Government and 
research funding bodies who are independent of pharmaceutical funding also have clear, 
often explicit research agendas.  Australia’s National Research Priorities 2011(10) (criteria 
against which funding is considered) identified four key aims for this year: “A healthy start to 
life”, “Ageing well, ageing productively”, “Preventive health care…prevent disease through 
the adoption of healthier lifestyles and diet…” and “Strengthening Australia’s social and 
economic fabric”.  
Although all very laudable ideas it is clear that the opportunity to produce research 
with internationally applicable results would be somewhat limited. 
The formulation of research questions are usually in line with national research 
priorities as such these have cultural bias. They are also methodologically biased with an 
emphasis placed on randomisation and epidemiologic outcomes. Such methods, although 
privileged by EBM hierarchies, are biased towards the type of questions that can be 
answered in such a quantitative manner (Kerridge (2010)(6). 
The conduct of research demonstrates a cultural bias with regards to recruitment. It 
has previously been reported that subjects in trials are most often white men (Keuken et al 
(2011)(11). Women and ethnic minorities are underrepresented as trial participants and as 
such the results of such trials cannot easily be extrapolated to these groups (Mastroianni et 
al (1994) cited Keuken et al (2011)(11)). Whilst this is concerning for philosophical reasons, 
there are direct pharmacological and physiological implications; some diseases are seen only 
in particular ethnic groups (ie Sickle Cell Disease) and some drugs are metabolising very 
differently by some people in different ethnic groups, an example of this the genetic 
variation in liver enzymes that effect warfarin metabolism clustering in different ethnic 
groups (Capodanno and Angiolillo (2010)(12). 
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The translation of research into clinical practice relies on the external validity of the 
results. If the environment in which the trial has been undertaken is not similar to where you 
may try to integrate the results into practice the meaningfulness of the results is 
questionable. This environment might be with regards to the patients included, the local 
expertise involved in patient care (for example to provision of high quality intensive care or 
radiology in the trial hospital), infrastructure differences for example the provision of a safe 
blood supply and the financial appropriateness of the therapy in question. 
The access to research results is dependent on access to the internet and either 
proficiency in reading English or access to translation. This again demonstrates cultural bias. 
This bias, evident at all levels of the production and incorporation of clinical research 
is such that the validity of any evidentiary claims made EBM must be reduced. 
This effect is most profound and exaggerated in Haematology where the 
incorporation of molecular techniques into evidence production is increasing. At the change 
of the millennia the development of molecular biological knowledge and technique has 
impacted greatly upon diagnosis, prognosis and targeted therapy. Such an approach has 
been widely adopted in haematology practice and as such has been at the forefront of 
technological and management developments. The practice of EBM based haematology 
exaggerates these biases and provides an elegant illustration in diagnosis and management 
of Acute Myeloid Leukaemia (AML). 
Whilst for the purpose of this paper we have chosen to use AML as the illustrative 
example, there are a number of different diseases within haematology which could easily 
have been selected.  
AML, until the advent of cytogenetic techniques was previously categorised 
according to one of eight morphological types dependent on the features identified under 
simple light microscopy; slide preparation and examination could be undertaken with 
minimal cost and a diagnosis could be made by anyone with training in morphological 
examination. The WHO classification of Tumours of Haematopoietic and Lymphoid Tissue 
now in a 4th edition (12) incorporates genetic abnormalities into a classification using both 
cytogenetic (the detection of large chromosomal abnormalities) and molecular (the 
detection of small gene specific abnormalities) techniques, and now recognises more than 
20 types of AML (Table 1). 
Table 1: WHO classification of Acute Myeloid Leukaemia and related myeloid neoplasms 
Acute Myeloid Leukaemia with recurrent cytogenetic abnormalities 
          AML with t(8:21)(q22;q22); RUNX1-RUNX1T1 
          AML with inv(16)(p13.1q22) or t(16;16)(p13.2;q22); CBFB-MYH11 
          AML with t(15;17)(q22;q12); PML-RARA 
          AML with t(9:11)(p22;q23);MLLT3-MLL 
          AML with t(6;9)(p23;q34); DEK-NUP214 
          AML with inv(3)(q21q26.2) or t(3:3)(q21;q26.2); RPN1-EVI1 
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          AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
          Provisional entity; AML with mutated NPM1 
          Provisional entity; AML with mutated CEBPA 
Acute myeloid Leukaemia with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
Acute myeloid Leukaemia, not otherwise specified 
           AML with minimal differentiation 
           AML without maturation 
           AML with maturation 
           Acute myelomonocytic leukaemia 
           Acute monoblastic/monocytic leukaemia 
           Acute erythroid leukaemias 
                     Pure erythroid leukaemia 
                     Erythroleukaemia; erythroid/myeloid 
           Acute megakaryoblastic leukaemia 
           Acute basophilic leukaemia 
           Acute panmyelosis with myelofibrosis 
Myeloid Sarcoma 
Myeloid Proliferations related to Down Syndrome 
           Transient abnormal myelopoiesis 
            Myeloid leukaemia associated with Down Syndrome  
Blastic plasmacytoid dendritic cell neoplasms 
 
The majority of these disease entities are dependent on the use of complex 
laboratory techniques, requiring significant technical skill and expensive hardware and 
consumables. For obvious reasons much of the non-developed world has no access to such 
techniques.  
It should be noted that the classification of the AML is not one made for intellectual 
interest alone but has a very significant impact on management and prognosis. Numerous 
molecular abnormalities have been identified as impacting on prognosis subdividing AML 
into “good”, “intermediate” and “poor” risk. “Good” risk AML includes “AML with inv 16” 
and “AML with t(8:21)”, these two disease entities have a significantly better prognosis than 
many other types of AML and as such are treated differently. Unlike for standard risk or poor 
risk AML in whom early SCT in first remission is recommended, the good risk patients are 
treated with chemotherapy alone (Wahlin (2009)(13). One other AML fits into the category 
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of “good risk”, AML with t(15:17) which interestingly appears to be a markedly different 
disease to other types of Myeloid Leukaemia. This form of AML is treated with medications 
(all trans retinoic acid and arsensic trioxide) aimed at maturing the leukaemic cells rather 
than primarily destroying cells (cytotoxic) unlike all other forms. Whilst there are some 
morphological characteristics (visible using a simple light microscope) the actual diagnosis of 
this subtype is entirely dependent on confirming the characteristic genetic abnormality and 
results in some 80% long term survival(14) compared with 60% 4 year survival  for the other 
good risk types(13). 
Further studies examining smaller molecular abnormalities have revealed an impact 
on prognosis. Mutations in exon 12 of the nucleophosmin (NPM1) gene are the most 
frequent abnormality in AN with normal cytogenetics (previously classed with 
“intermediate” risk AML) seen in up to 60%(15) of patients and nnow confers a good 
prognosis for those originally classed as intermediate risk. This is compared with those 
patient in whom an internal tandem duplication mutation of FLT3 with a normal karyotype 
who are now reclassified from an intermediate risk disease to one of high risk and 
consequent poor prognosis. 
 As more molecular abnormalities are identified as having an influence on prognosis, 
studies are making recommendations for such grave differences in management as whether 
or not to proceed to a bone marrow transplant when the patient achieves a remission based 
on the detection of a single mutation. 
With the advent of more and more published studies on the effect that these 
molecular abnormalities have on prognosis and management, comes the realisation that 
lack of access to the techniques required to make the classification results not only in a 
significant disadvantage in making the diagnosis but the suggestion that we are now dealing 
with entirely different disease entities. Those experiencing AML in Africa are unable to have 
the same diagnosis as those in Australia. 
The disadvantages experienced by AML patients in the non-developed world extend 
beyond that of diagnosis to the availability of appropriate therapies. Even prior to the most 
recent classifications of AML the mainstay of treatment relied on the use of combination 
infusional combined chemotherapy protocols. For such an approach to work not only does 
one require access to these medications (at not inconsiderable cost) but also to high level 
supportive care in the form of safe and easily available blood products (such as red cell 
concentrates and platelets) for transfusion, broad spectrum intravenous antibiotics for the 
management of febrile neutropenia and access to high levels of nursing and medical 
expertise. In our centre the cost of drugs alone to provide induction and consolidation 
chemotherapy to a patient with standard risk AML is in the order of AU$ 23,160 (this is 
based on non-subsidised figures and does not include the costs of additional medications 
such as intravenous antibiotics or GCSF).  This is clearly not available in a large proportion of 
the world. As the role of bone marrow transplant (stem cell transplant) became more 
apparent the use of SCT when a patient had achieved a first remission became 
recommended for patients who were considered high risk became incorporated throughout 
the developed world. Once again the criteria for risk are based on advanced genetic testing 
and are not easily available. In Australia the average cost of a SCT from a sibling is $114,000 
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for an adults and $227,286 for a child for the first 3 months of care (Gordon et al (2009)(16). 
The resources required, both absolute financial cost as well as medical expertise are 
prohibitive for such an approach in most of the world. As each new gene abnormality is 
detected targeted therapies such as FLT3 inhibitors are incorporated into therapeutic trials. 
Those experiencing AML in Africa are unable to have the same treatment as those in 
Australia. 
There is, of course, little in the way of published evidence in the management of 
AML in communities without access to such diagnostic and management approaches. When 
the majority of RCTs incorporating medical therapies are sponsored by pharmaceutical 
companies, the impetus to perform studies that utilise the few diagnostic and management 
techniques available is negligible. Those few studies using patients in countries such as this 
are performed not to identify the “best evidence based” approach for the management of 
AML in these communities but as a means of increasing subject numbers or reducing trial 
costs and as such produce a meaningless evidence base for the care of these patients off 
trial. 
Let us pause for a moment and consider this patient in Africa; they are unable to 
have a disease classification, we are unable to use published evidence to help prognosticate 
for them and we are unable to provide the same treatment for them. Consequently we can 
no longer, by any stretch of the imagination, claim that the African and Australian patients 
have the same disease. Whilst the use of published evidence (and therefore EBM) is 
impractical with regards to cost and accessibility, it is perhaps more alarmingly, meaningless 
for the African patient. 
For these reasons EBM now creates an epistemological and ontological crisis for 
medicine. We can no longer classify or understand, what is fundamentally perhaps the same 
disease process in our African and Australian patient, in the same way, our “knowing” is 
different. This disparity of knowing is the direct result of EBM and the creation of a two 
tiered approach to what was although biologically likely to have been the same disease, can 
no longer be thought of as such. Whether we classify this bias as cultural, geographical or 
financial we are left with a grossly biased approach to health care that is meaningless to 
more than 90% of the world and serves to widen the disparity in health outcomes in the 
medically non-developed world. 
 There are a number of ways in which this cultural bias could be overcome. Firstly the 
impossibility of the incorporation of current published evidence must be acknowledged, a 
transparency with regards to the idea that evidential “standards do not operate outside of 
the social context” (Goldenberg (2010)(8)) must be pursued. By doing this, the pressure to 
implement the management described in such studies is reduced and allows for the 
consideration of other justice related factors in clinical care as outlined by Rogers (2004)(7). 
Secondly the biases of biomedical journals toward the publication of research from the 
geographical North needs to be overcome to not only reduce the effects of socio-economic 
factors on study outcomes but also to allow for physiological ethnic differences in treatment 
effects to be reviewed. The development of institutional or clinician partnerships between 
countries of varying wealth and expertise will allow for an increase in the applicability of 
current evidence. By either providing assistance in developing local diagnostic techniques or 
7 | P a g e  
 
by providing a satellite diagnostic centre we would be able to once again begin to 
understand the disease of patient from both countries in the same way. Either the 
production of locally relevant research utilising pragmatically available therapies or 
consideration of current research within a locally feasible framework may allow for a 
treatment approach that benefits local patients and results in some positive outcomes. 
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